Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, toward Phase 2 clinical trials while simultaneously generating commercial revenue from its over-the-counter product unbuzzd, according to Executive Co-Chairman and Co-Founder Anthony Durkacz. In a recent BioMedWire Podcast interview, Durkacz outlined the company's strategy for addressing multiple sclerosis (MS) and building a diversified portfolio spanning neurodegenerative, metabolic, and alcohol-misuse conditions.
Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of MS. The company has filed an investigational new drug application for a Phase 2 clinical trial, which could mark the first administration of Lucid-MS to human MS patients. The candidate aims to address mobility damage associated with MS, a significant unmet need in the neurodegenerative disease space. According to the press release, Quantum BioPharma's subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, which has shown promise in preclinical models.
Alongside its clinical pipeline, Quantum BioPharma is pursuing commercial growth through unbuzzd, a product designed to accelerate alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI (as of March 31, 2026) and is entitled to royalty payments: 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma also retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The unbuzzd product is available at www.unbuzzd.com.
This dual approach allows Quantum BioPharma to generate near-term revenue from unbuzzd while advancing Lucid-MS through clinical development. For investors and industry observers, the strategy highlights a path to funding clinical trials through commercial sales, potentially reducing dilution risks. The MS drug candidate, if successful, could address a large global market, as multiple sclerosis affects approximately 2.8 million people worldwide. The company's focus on myelin repair is a differentiated approach compared to many existing MS therapies that primarily target inflammation.
Durkacz emphasized during the podcast that the combination of clinical-stage pharmaceutical development and commercial opportunities positions the company to address challenging conditions across neurodegenerative, metabolic, and alcohol-misuse disorders. The company's newsroom, available at https://ibn.fm/QNTM, provides updates on its progress.
For leaders in business and technology, Quantum BioPharma's strategy illustrates how biotech firms can leverage commercial products to support long-term research and development. The success of unbuzzd could provide a steady revenue stream to fund Lucid-MS trials, while a positive outcome for Lucid-MS would represent a significant advancement in MS treatment. The company's approach may serve as a model for other clinical-stage firms seeking to balance innovation with financial sustainability.
